Itamar Medical
Home Sleep Testing and Endothelial Function Assessment
Company Overview
Snapshot
Founded in January 1997, Itamar Medical is a medical device company with 201–500 employees. The company raised a total of $190.45 million across 10 funding rounds from 11 investors. In September 2021, Itamar Medical was acquired by ZOLL Medical for approximately $538 million.
Business overview
Itamar Medical is a medical device company specializing in integrating sleep apnea management into cardiac patient care pathways. The company develops, manufactures, and sells the FDA-cleared WatchPAT diagnostic product line, which utilizes the biological PAT signal for simple, comprehensive, and scalable diagnosis of respiratory sleep disorders. Additionally, Itamar Medical offers the EndoPAT system, an endothelial function assessment tool for risk classification. The company operates in the Health Tech & Life Sciences sector, focusing on digital healthcare, patient remote monitoring, and diagnostic medical devices, serving healthcare providers and patients globally.
Strategic signal
In September 2021, Itamar Medical was acquired by ZOLL Medical for approximately $538 million. This acquisition signifies a strategic move to enhance ZOLL's offerings for undiagnosed and untreated cardiac patients by integrating Itamar Medical's non-invasive medical devices and digital health solutions for respiratory sleep disorders. For investors, this indicates strong validation of Itamar Medical's technology and market position, highlighting the increasing value placed on integrated care pathways for sleep apnea and cardiac health.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent corporate development for Itamar Medical?
- In September 2021, Itamar Medical was acquired by ZOLL Medical Corporation for approximately $538 million. This acquisition aimed to accelerate the advancement of home sleep medicine and enhance ZOLL's offerings for cardiac patients.
- What was Itamar Medical's financial performance in Q2 2021?
- Itamar Medical reported a 41% year-over-year increase in revenues to $12.6 million for Q2 2021. U.S. WatchPAT revenues specifically increased by 53% year-over-year to $10.1 million.
- What product enhancements did Itamar Medical introduce in June 2021?
- In June 2021, Itamar Medical expanded the capabilities of its WatchPAT at-home sleep apnea diagnostic testing line. New features included WatchPAT with SleePath, allowing users to document subjective data, and WatchPAT ONE-M, an enhancement to its single-night disposable sleep apnea test.
- Did Itamar Medical make any acquisitions in early 2021?
- In January 2021, Itamar Medical acquired technology and assets from Spry Health, a company specializing in wrist-based medical-grade remote patient monitoring. This acquisition was intended to enable Itamar Medical to develop a continuous sleep apnea monitoring device and expand its presence in chronic disease management.
- What was the outcome of Itamar Medical's Nasdaq offering in February 2021?
- In February 2021, Itamar Medical raised $70 million in a secondary offering on Nasdaq, with investor. The company's share price rose 7.25% following the offering.